Mahamaya Lifesciences Ltd.
Closed
BSE SME
SME
Live Chart
| Category | Subscription | Shares Offered | % of Total | Amount (₹Cr) |
|---|---|---|---|---|
|
Market Maker
|
Awaited |
309,600
5.01% |
5.01%
|
₹3.53 |
|
QIB
|
Over 1.00x
|
2,928,000
47.39% |
47.39%
|
₹33.38 |
|
NII / HNI
|
Over 1.00x
|
882,000
14.27% |
14.27%
|
₹10.05 |
|
Retail
|
Over 1.00x
|
2,059,200
33.33% |
33.33%
|
₹23.47 |
| Total | 1.00x | 6,178,800 |
100% | ₹70.44 |
| Category | Shares Offered | Amount (₹Cr) | Size (%) |
|---|---|---|---|
| QIB | 2,928,000 | ₹33.38 |
47.39%
|
| Market Maker | 309,600 | ₹3.53 |
5.01%
|
| NII | 882,000 | ₹10.05 |
14.27%
|
| Retail | 2,059,200 | ₹23.47 |
33.33%
|
| Total | 6,178,800 | ₹70.44 |
100.00%
|
| QIB | NII | Retail | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor | Total QIB | Below ₹10L | Above ₹10L | Total NII | |||
| Allocation (shares) | — | — | — | — | — | 882,000 | 2,059,200 | 2,941,200 |
| Allotment price (₹) | 114 | 114 | 114 | 114 | 114 | 114 | 114 | 114 |
| No. of applications | — | — | — | — | — | — | — | — |
| No. of shares applied | — | — | — | — | — | — | — | — |
| Amount collected (₹Cr) | — | — | — | — | — | — | ₹23.47 | ₹23.47 |
| Times subscribed | 1 | — | — | — | — | 1 | 1 | 1 |
| Shares allotted | — | — | — | — | — | 882,000 | 2,059,200 | 2,941,200 |
| No. of allottees | — | — | — | — | — | — | — | — |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 2,400 | ₹273,600 |
| Retail (Max — 13 Lots) | 13 | 15,600 | ₹1,778,400 |
| S-HNI (Min — 14 Lots) | 14 | 16,800 | ₹1,915,200 |
| B-HNI (Min — 68 Lots) | 68 | 81,600 | ₹9,302,400 |
Mahamaya Lifesciences Ltd. is proposing an IPO on BSE SME under the SME category. Total issue: 61,78,800 shares (aggregating up to ₹70.44 Cr).
Opens 11 Nov 2025, closes 13 Nov 2025. Listing: 21 Nov 2025. Apply via ASBA or UPI.
| Particulars | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue from Operations | 84.04 | 267.17 | 162.83 |
| EBITDA | 8.04 | 24.64 | 13.36 |
| Profit After Tax (PAT) | 4.10 | 12.94 | 5.22 |
| Net Worth | 53.50 | 49.42 | 24.66 |
| Total Assets | 218.87 | 188.35 | 112.07 |
| Reserves & Surplus | 35.73 | 31.66 | 23.41 |
| Borrowings | 57.72 | 58.11 | 54.63 |
| EBITDA Margin (%) | 9.22% | — | — |
| PAT Margin (%) | 4.84% | — | — |
Mahamaya Lifesciences Ltd. IPO is subscribed 1.00 times by Nov 13, 2025. Retail: 1.00x. QIB: 1.00x. NII: 1.00x.
| Investor Category | Subscription |
|---|---|
| Qualified Institutional (QIB) | 1.00x |
| Non Institutional (NII/HNI) | 1.00x |
| Retail Individual | 1.00x |
| Total Subscription | 1.00x |
The Mahamaya Lifesciences Ltd. IPO retail category is subscribed 1.00 times as of 13 Nov 2025. The retail portion is oversubscribed.
Subscribe via your broker app using ASBA or UPI. Opens 11 Nov 2025 and closes 13 Nov 2025. Min investment: ₹136,800 (1 lot = 1,200 shares). UPI mandate: 2025-11-13.
The Mahamaya Lifesciences Ltd. IPO subscribed 1.00x overall. QIB: 1.00x, NII: 1.00x, Retail: 1.00x. Applications: from NSE/BSE.
Check allotment on the registrar website. Enter your PAN, application number or DP/Client ID. Allotment date: 19 Nov 2025. Refunds: on 20 Nov 2025.
The Mahamaya Lifesciences Ltd. IPO listing date is 21 Nov 2025, Friday. Listed on: BSE SME. Issue price: ₹114. Estimated listing: ₹114. GMP: NIL.
The Mahamaya Lifesciences Ltd. IPO closes on 13 Nov 2025, Thursday. UPI mandate: 2025-11-13. Allotment: 19 Nov 2025. Listing: 21 Nov 2025.